William Blair analyst Andrew Brackmann has reiterated their bullish stance on DGX stock, giving a Buy rating on July 11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Brackmann’s rating is based on Quest Diagnostics’ strong second-quarter performance, which exceeded expectations across key financial metrics. The company reported a notable increase in total revenue and adjusted earnings per share, both surpassing consensus estimates. This performance was driven by robust organic net revenue growth, particularly in Diagnostic Information Services, and an improved operating margin.
Furthermore, Quest Diagnostics increased its full-year guidance for both revenue and adjusted earnings per share, indicating confidence in its continued growth trajectory. The updated guidance reflects a higher organic revenue growth expectation and suggests potential for further margin expansion. These positive developments, alongside stable pricing and a promising M&A pipeline, underpin Brackmann’s Buy rating, as they are likely to sustain investor confidence and support share price appreciation.
In another report released on July 11, TR | OpenAI – 4o also upgraded the stock to a Buy with a $192.00 price target.